Merck KGaA

Request correction

Corporate brand

Unclaimed Read 4× by AI crawlers

German multinational science and technology company operating across healthcare, life science and electronics.

Last updated October 15, 2026

AI crawler reads

4requests

1companies

Anthropic4

Profile: 2
Controversies: 2
JSON · MD: 0

First read: Nov 4, 2026
Latest read: Nov 4, 2026

From this site's server log

Overview

Merck KGaA, commonly branded as Merck, is a German science and technology company headquartered in Darmstadt. Its activities span three principal sectors: Healthcare, Life Science and Electronics. The group develops prescription medicines and therapies, supplies laboratory and biopharmaceutical manufacturing technologies, and produces advanced materials used in displays, semiconductor fabrication and other high-technology applications. The company traces its origins to the Engel pharmacy in Darmstadt, acquired by Friedrich Jacob Merck in 1668. In the nineteenth century, Emanuel Merck transformed the pharmacy into an industrial chemical and pharmaceutical operation. He isolated and manufactured alkaloids and other active substances in standardized quantities, helping establish the business as a supplier to pharmacies and medical manufacturers. Merck was an early commercial producer of morphine and cocaine, although these historical activities belong to a very different regulatory and medical era. Merck’s history is closely connected with the wider Merck family and with the similarly named American company now known as Merck & Co. The American business began as a Merck subsidiary in 1891 but became independent after its confiscation during the First World War. Merck KGaA retains the Merck trademark in most countries, while its North American businesses generally use EMD, EMD Serono, MilliporeSigma and EMD Electronics branding. The distinction has led to recurring trademark disputes and public confusion. For much of its history Merck was privately held by the Merck family. It became a publicly traded German partnership limited by shares in 1995, while the family retained control through E. Merck KG. The company expanded substantially during the 2000s and 2010s through acquisitions, particularly in biotechnology, laboratory science, electronic materials and bioprocessing. Purchases of Serono, Millipore, Sigma-Aldrich, AZ Electronic Materials, Versum Materials and other businesses broadened Merck from a traditional chemicals and pharmaceuticals company into a diversified technology group. Healthcare includes innovative medicines, fertility treatments, endocrinology, neurology and immuno-oncology. Life Science provides laboratory reagents, analytical products, filtration systems, process equipment and raw materials used in research, diagnostics and the manufacture of biologic medicines. Electronics supplies liquid-crystal and other display materials, semiconductor process chemicals, delivery systems and advanced materials. Merck serves customers ranging from hospitals and universities to pharmaceutical manufacturers, chipmakers and consumer-electronics companies. The group operates internationally through hundreds of subsidiaries and uses different commercial names where trademark rights require them. Its long-term positioning combines scientific research with industrial-scale production, with a particular emphasis on specialized, highly regulated or technically demanding markets rather than mass-market consumer products. In recent years it has increased its focus on oncology, immunology, neurology, biopharmaceutical production, mRNA-related capabilities and semiconductor materials while divesting or reshaping selected non-core activities.

History

Merck KGaA's history begins with the Merck family's pharmacy in Darmstadt, established in 1668. The business gradually moved beyond retail pharmacy into chemical and pharmaceutical production, building an industrial base around active ingredients, specialty chemicals, and laboratory-related products. Its long history is central to the group's corporate identity, although the present-day company is the result of extensive modernization, internationalization, portfolio restructuring, and acquisitions. During the nineteenth and twentieth centuries, Merck developed as a research-oriented chemical and pharmaceutical enterprise. Its activities expanded into medicines, laboratory chemicals, and industrial technologies. International operations and licensing arrangements became increasingly important, while the business developed specialized expertise in pharmaceutical research and chemical manufacturing. The company ultimately adopted the corporate form Merck KGaA, with E. Merck KG serving as the family's general partner and a publicly traded limited partnership structure providing outside investment. In the modern period, Merck organized its activities into healthcare, life science, and performance materials, with the latter later evolving into the Electronics business. Healthcare has focused on specialty pharmaceuticals, including neurology, fertility, immunology, and oncology-related areas. The Life Science business was significantly enlarged by the acquisition of Sigma-Aldrich, which created a broad supplier of laboratory products, research reagents, and biopharmaceutical manufacturing materials. Electronics has developed materials and solutions for display technologies and semiconductor fabrication, giving the group exposure to industrial technology markets in addition to healthcare. The company has also pursued targeted acquisitions to strengthen technology platforms and pharmaceutical pipelines. Purchases and investments in businesses such as Versum Materials and Intermolecular expanded its semiconductor-materials capabilities. In healthcare, acquisitions and partnerships have been used to add late-stage candidates, specialist medicines, and therapeutic technologies. The SpringWorks transaction further emphasized rare tumors and specialty oncology, while the proposed Bio-Techne transaction was presented as a way to deepen Merck KGaA's position in fast-growing life-science markets. Merck's brand architecture requires careful geographic interpretation. Merck KGaA uses the Merck name in much of the world but operates as EMD in the United States and Canada in several contexts. Merck & Co., Inc. is a separate American company that uses Merck in the United States and Canada and MSD in many other countries. Confusion between the two organizations has affected media reports, search results, and commercial descriptions. This dossier therefore limits the selected subject to the Darmstadt-based Merck KGaA and excludes products, executives, and transactions clearly belonging to Merck & Co.

2026
Bio-Techne acquisition agreement
[1]Merck KGaA, Darmstadt, Germany, agrees to acquire Bio-Techneprnewswire.com
Merck KGaA agreed to acquire Bio-Techne to strengthen its life-science tools, multi-omics, analytics, and bioprocessing offerings.
2025
SpringWorks acquisition completed
[2]Merck concludes SpringWorks acquisitionfinance.yahoo.com
Merck completed the acquisition of SpringWorks Therapeutics, adding medicines for rare tumors and related specialty-care opportunities.
2019
Versum Materials acquisition announced
Merck expanded its electronics and semiconductor-materials activities through the acquisition of Versum Materials.
2015
Sigma-Aldrich acquisition completed
Merck completed the acquisition of Sigma-Aldrich, substantially expanding its laboratory, research, and bioprocessing portfolio.
1668
Merck family pharmacy established
The Merck family pharmacy in Darmstadt, associated with Friedrich Jacob Merck, became the historical origin of the company.

Products and positioning

A science-led, globally diversified company combining healthcare, life-science tools and services, and electronics materials.

Prescription medicine
Mavenclad
Mavenclad is an oral multiple-sclerosis medicine marketed by Merck KGaA's healthcare organization. The product is associated with a treatment schedule designed around defined courses rather than continuous daily dosing, making its dosing pattern a central part of its patient and healthcare-professional communication. In the United States and Canada, Merck KGaA's pharmaceutical activities are commonly associated with EMD Serono.
Life-science tools
Sigma-Aldrich portfolio
The Sigma-Aldrich portfolio includes laboratory reagents, chemicals, analytical products, research materials, and supplies used by academic, pharmaceutical, biotechnology, and industrial laboratories. It forms part of Merck KGaA's broad life-science offering and supports work ranging from basic research to biopharmaceutical development and manufacturing.
Laboratory water purification
Milli-Q
Milli-Q is Merck's laboratory water-purification platform. It is used to produce purified water for analytical, research, and laboratory workflows, with systems and consumables designed for different laboratory requirements and quality levels.
Semiconductor and display materials
Electronics materials
Merck's Electronics business supplies materials and related technologies for semiconductor fabrication, displays, and other advanced electronic applications. The portfolio reflects the group's move beyond traditional pharmaceuticals into specialized materials that support manufacturing processes and next-generation device technologies.

Controversies

2021
Merck files Januvia patent suit against Laurus
Merck Sharp & Dohme Corp. filed a patent suit in the District of Delaware against Laurus Labs Limited and Laurus Generics Inc. after the defendants submitted an ANDA to the FDA seeking to produce a generic version of Januvia. Merck is seeking a declaration of patent infringement; the filing describes the alleged infringement, not a court determination.
Source
2021
Gardasil injury lawsuit filed against Merck
Robert F. Kennedy Jr. says he and Baum Hedlund filed a lawsuit against Merck alleging that its Gardasil HPV vaccine caused severe, life-changing injuries. The claims are allegations; the source reports no court determination.
Source
2016
United Kingdom trademark ruling involving Merck & Co.
The High Court of Justice in the United Kingdom held that Merck & Co. had breached an agreement and infringed Merck KGaA’s rights through use of the Merck name in circumstances directed at the UK market.
Source
2016
Trademark dispute with the German Merck Group
Merck & Co. and the German Merck Group continued to contest the use of the Merck name in various jurisdictions, reflecting their separate corporate histories and territorial trademark arrangements.
Source
2009
Sponsored medical-journal supplements
Merck’s Australian affiliate paid Elsevier to produce medical-journal issues that presented reprinted, favorable material without clearly identifying the commercial sponsorship. The practice became public during Vioxx litigation and was acknowledged by an Elsevier executive as unacceptable.
Source
2007
Generics UK price and supply-fixing settlement
Merck’s former British Generics business paid an out-of-court settlement to the UK Department of Health and Social Care concerning allegations that drug companies restricted supplies and increased prices for medicines supplied to the National Health Service.
Source
2004
Merck withdraws Vioxx worldwide
Merck voluntarily removed the COX-2 painkiller Vioxx from worldwide markets after evidence linked prolonged use with increased cardiovascular risk.
Source
2004
Vioxx safety controversy and withdrawal
Merck withdrew Vioxx after clinical evidence indicated increased cardiovascular risks associated with certain patterns of use. The withdrawal generated extensive personal-injury litigation and criticism concerning risk evaluation, disclosure, and marketing.
Source
1991
Kelco air-emissions pollution
Merck subsidiary Kelco was linked to volatile-organic-compound emissions in the San Diego area. Merck later paid an environmental penalty and installed equipment intended to reduce emissions.
Source
1933
Merck’s activities during the Nazi period and wartime forced labor
Historical accounts describe the political roles of company leader Karl Emanuel Merck during Nazi rule, the production of war-related chemicals and pharmaceuticals, and the use of forced laborers at the Darmstadt plant during the Second World War.
Source

2026
Agreement to acquire Bio-TechneM&A
Background
Merck KGaA identified life-science tools, multi-omics, analytical technologies, bioprocessing, and advanced therapeutics as growth areas requiring broader capabilities.
Action taken
The company agreed to acquire Bio-Techne in an all-cash transaction, subject to customary conditions and approvals.
Aftermath
The proposed combination was presented as a means of broadening Merck KGaA's offering across the research and biopharmaceutical value chain; the supplied material does not establish final completion.
Enterprise value. US$11.3 billion (Transaction announcement, June 2026)
Source

Recent events

2026.10.29
Reported2026.10.29
Merck raises adjusted profit outlook[7]默克上调调整后利润展望cnbc.com
Merck raised its adjusted earnings outlook to $2.77–$2.82 per share, from its previous range of $2.66–$2.76 per share.
2026.10.29
Reported2026.10.29
Merck opens bioprocessing production center in Daejeon[8]默克在大田开设生物工艺生产中心finanznachrichten.de
Merck opened its Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea, expanding its regional manufacturing capacity for materials and solutions used in biologic medicines.
2026.10.14
Reported2026.10.14
Merck officially opens 120,000-square-foot Advance research facility at West Point, Pennsylvania campus[9]默克在宾夕法尼亚州西点园区正式启用12万平方英尺的Advance研发设施cnbc.com
Merck on Wednesday (Oct 14, 2026) officially opened its new 120,000-square-foot research facility, named Advance, on its West Point, Pennsylvania campus, with a ribbon-cutting ceremony attended by Pennsylvania Gov. Josh Shapiro and other officials. The facility features highly automated robotic systems and advanced digital AI capabilities. Speaking after the opening, Merck CEO Rob Davis told CNBC he expects the company's personalized cancer vaccine developed with Moderna to become faster to manufacture over time, while noting the current focus is ensuring supply and market readiness for the vaccine, which is paired with Keytruda.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
2022.02.16
Reported2022.02.16
Unlearn and Merck KGaA announce multi-year collaboration[10]Unlearn与默克宣布多年合作finanznachrichten.de
Unlearn announced a multi-year collaboration with Merck KGaA to accelerate late-stage clinical trials using trial designs that include Digital Twins. The collaboration will initially focus on advancing regulatory approval of candidates in Merck KGaA's immunology pipeline, with potential to expand to other therapeutic areas.
2022.01.05
Reported2022.01.05
Merck and Palantir partner on Athinia platform[11]默克与Palantir合作打造Athinia平台chinatimes.com
Merck announced a partnership with Palantir Technologies to develop Athinia, a secure collaborative data analytics platform for the semiconductor industry.
Unconfirmed
Reported2022.01.05
Merck KGaA exercises fourth licensing option in F-star collaboration[12]默克集团在与F-star的合作中行使第四项许可选择权finance.yahoo.com
Merck KGaA exercised a fourth licensing option in its immuno-oncology collaboration with F-star Therapeutics.
2021.12.23
Reported2021.12.23
FDA authorizes Merck’s COVID-19 pill[13]FDA授权默克新冠口服药999ktdy.com
The U.S. Food and Drug Administration authorized Merck’s molnupiravir for treatment of mild-to-moderate COVID-19 in adults at risk for severe disease when alternative treatments are not accessible or clinically appropriate.
2021.12.21
Merck to acquire Chord Therapeutics[14]默克将收购Chord Therapeuticsbiospectrumindia.com
The article reports that Chord Therapeutics is being acquired by Merck. The acquisition is intended to expand Merck's neurology pipeline and support development of Chord's lead drug candidate, CRD1.
2021.12.14
Reported2021.12.14
Merck announces investment in Taiwan[15]默克宣布在台湾投资chinatimes.com
Merck announced plans to invest approximately NT$17 billion in Taiwan over the next five to seven years to expand electronic technology production lines and R&D capacity. The plan is expected to create about 400 jobs.
2021.11.22
Reported2021.11.22
Merck completes acquisition of Acceleron Pharma[16]默克完成对 Acceleron Pharma 的收购investingnews.com
Merck announced that it had successfully completed its acquisition of Acceleron Pharma Inc.

Sources101 sources

Cite this profile: Cite the canonical profile. /brand-wiki/merck · Editorial policy · How profiles are compiled